Apr 26, 2017
It’s April, which in Japan means baseball is back, and cherry blossoms are in full bloom (side note: April really is the best time to visit Japan for those considering a trip). April is also the start of the 2nd quarter, and at Locust Walk Japan we have noticed a...
Apr 5, 2017
While border control is one of today’s biggest hot-button political topics, US biotech companies are clearly not building any walls when it comes to deal-making. In fact, Locust Walk views regional deal-making outside of the US as a significant value driver for US...
Mar 23, 2017
I recently had the pleasure to conduct a podcast conversation with Bradley Campbell, who is the President and Chief Operating Officer of Amicus Therapeutics (listen to the podcast here). Bradley recounted the interesting history of Amicus’ development of Galafold™...
Mar 15, 2017
With the election of President Trump and a Republican congress last November, many (including Locust Walk) have speculated on the future of pricing, reimbursement, drug approval and other potential policy changes and their potential impact on the biopharma industry....
Dec 7, 2016
This week Locust Walk announced the opening of our first office in Europe, which will initially be in Germany. Since this is a big step for our firm and builds on our success in Japan, we wanted to share the rationale for why we thought going into Europe made sense....
Dec 1, 2016
The recent flurry of partnering deals for Immuno-Oncology (IO) technologies surpasses the deal activity for any other technology at any other time in biotech history. In the past two years, there have been 31 development stage IO deals with up-front values greater...
